A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact: Study coordinator (Margaret Thomas, MPH) · margaretannthomas@uabmc.edu
Contact: Principal Investigator (Mehmet S Akce, MD)

Study leads

Mehmet Akce, MD
Principal Investigator
University of Alabama at Birmingham

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Taoyuan City, Taiwan

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

HCC - Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2, PHASE3

Shanghai, China

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Lanzhou, China · Guangzhou, China

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China